A recent study used difference-in-difference analysis to assess adalimumab sales volumes and expenditures in 6 countries with ...
On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details ...
Ha Kung Wong, JD, an intellectual property attorney, discusses lawsuits by drug companies aimed at delaying competition from biosimilars, but the effectiveness of these lawsuits in hindering ...
The Association for Accessible Medicines’ report on Medicare Part D tiering revealed low coverage rates for insulin and ...
Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales ...
Two senators reintroduce the Increasing Access to Biosimilars Act, a bipartisan bill aimed at boosting competition and ...
Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to ...
A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel ...
In its latest earnings report, Sandoz championed 7% growth overall throughout 2023, including a 15% spike in biosimilar ...
Patients with rheumatoid arthritis (RA) that did not respond well to methotrexate experienced no difference in efficacy, safety, immunogenicity, or pharmacokinetic (PK) profiles when they switched to ...
A large-scale study found that Omnitrope, a biosimilar growth hormone, is effective and well-tolerated in treating various ...